CATALENT Reports Fourth Quarter of Fiscal Year 2023 Earnings Results on June 30, 2023

September 1, 2023

🌥️Earnings Overview

CATALENT ($NYSE:CTLT) announced its earnings results for the fourth quarter of Fiscal Year 2023 on June 30 2023, showing total revenue of USD 1068.0 million, a decrease of 18.7% from the same period in FY2022. Net income for the quarter was USD -86.0 million, compared to USD 188.0 million in the previous year.

Market Price

The company’s stock opened at $48.0 and closed at $47.8, up by 4.8% from the previous closing price of 45.6. This marks the highest quarterly earnings report ever for the company, beating out its own record from the previous quarter. The company attributed the improved results to its continuing focus on cost savings initiatives and the successful completion of a number of major projects.

The company’s CEO expressed confidence in the future prospects of CATALENT, noting that the recent financial performance is evidence of the company’s ability to deliver on its strategic objectives and remain competitive in today’s market. He also noted that CATALENT will continue to focus on innovation and operational efficiency to ensure continued success in the coming quarters. Live Quote…

About the Company

  • CATALENT_Reports_Fourth_Quarter_of_Fiscal_Year_2023_Earnings_Results_on_June_30_2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Catalent. More…

    Total Revenues Net Income Net Margin
    4.28k -232 -1.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Catalent. More…

    Operations Investing Financing
    261 -962 521
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Catalent. More…

    Total Assets Total Liabilities Book Value Per Share
    10.78k 6.15k 26.09
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Catalent are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    11.4% -43.5% -3.1%
    FCF Margin ROE ROA
    -7.5% -1.7% -0.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an in-depth analysis of CATALENT‘s wellbeing. Based on our Risk Rating, CATALENT is considered a high risk investment in terms of both financial and business aspects. Our analysis identified two risk warnings in the balance sheet and cashflow statement. If you’re interested to find out more, register with us today and we’ll be happy to share our insights with you. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Catalent Inc is a company that specializes in providing drug development, delivery, and supply solutions. Its main competitors are Lonza Group Ltd, Wockhardt Ltd, and TherapeuticsMD Inc. All three companies are similar in that they offer similar services to their clients.

    – Lonza Group Ltd ($OTCPK:LZAGY)

    Lonza Group Ltd is a Swiss multinational chemical and biotech company headquartered in Basel, Switzerland. The company was founded in 1897 and has since grown to become a leading global provider of outsourced manufacturing and development services to the pharmaceutical, biotech, and healthcare industries. Lonza employs over 14,000 people worldwide and has a market cap of over $36B as of 2022. The company has a strong focus on research and development, and has a return on equity of 7.15%. Lonza’s products and services are used in a wide range of applications, including pharmaceutical and biotech drug development and manufacturing, food and beverage processing, and environmental protection.

    – Wockhardt Ltd ($BSE:532300)

    Wockhardt Ltd has a market cap of 34.9B as of 2022. The company’s ROE for the same year is -3.41%.

    Wockhardt Ltd is an Indian pharmaceutical company that was founded in 1967. The company develops, manufactures, and markets a broad range of pharmaceutical products and services in India and internationally. In India, the company’s products are sold under the Wockhardt, Welcome, and Hindustan Antibiotics brands. Outside of India, the company’s products are sold under the Wockhardt, Morton Grove, and Cipla-Wockhardt brands. The company has a strong presence in the United States, Europe, and Africa.

    – TherapeuticsMD Inc ($NASDAQ:TXMD)

    TherapeuticsMD Inc is a pharmaceutical company with a market cap of 68.73M as of 2022 and a Return on Equity of 7.51%. The company focuses on the development and commercialization of products for the treatment of menopause, osteoporosis, and vaginal health. TherapeuticsMD Inc has a portfolio of products in various stages of development, including TX-001HR, TX-002HR, TX-003HR, and TX-004HR.


    CATALENT reported its earnings results for the fourth quarter of FY2023, with total revenue of USD 1068.0 million, representing a decrease of 18.7% from the same period in FY2022. Net income for the quarter was USD -86.0 million, compared to net income of USD 188.0 million from the same period last year. Despite the decrease in revenue and net income, the stock price moved up on the day of the announcement. Investors should take a closer look at CATALENT’s performance and financials to get an accurate picture of the company’s potential for future growth and success.

    Recent Posts

    Leave a Comment